Management of sildenafil treatment failures

Current Opinion in Urology

Volumn 16, Issue 6, 2006, Pages 449-459

  Kendirci, Muammer ^a   Tanriverdi, Orhan ^a   Trost, Landon ^b   Hellstrom, Wayne J G ^b  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Combination; Erectile dysfunction; Failure; Management; Sildenafil

Indexed keywords

ALFUZOSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOMORPHINE; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVACECARNINE; LOSARTAN; METOPROLOL; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROPIONYLCARNITINE; PROPRANOLOL; PROSTAGLANDIN E1; SILDENAFIL; TESTOSTERONE; VARDENAFIL; VASOACTIVE AGENT;

CLINICAL TRIAL; COMORBIDITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; EXERCISE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; NONHUMAN; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT SATISFACTION; PENIS PROSTHESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

COUNSELING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; IMPOTENCE; MALE; MUSCLE, SMOOTH, VASCULAR; PENILE IMPLANTATION; PIPERAZINES; TREATMENT FAILURE; VASODILATOR AGENTS;

EID: 33750357114     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000250286.60237.a6     Document Type: Review

References (84)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270:83-90.
2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84:50-56.
3. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151:54-61.
4. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75:191-236.
5. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342:1802-1813.
6. Kim N, Azadzoi KM, Goldstein I, Saenz de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991; 88:112-118.
7. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13:282-290.
8. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction Sildenafil Study Group. N Engl J Med 1998; 338:1397-1404.
9. Seidman SN, Roose SP, Menza MA, et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001; 158:1623-1630.
10. Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998; 51:1629-1633.
11. Sanchez Ramos A, Vidal J, Jauregui ML, et al. Efficacy, safety and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord 2001; 39:637-643.
12. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 2001; 44:1296-1301.
13. Incrocci L, Koper PC, Hop WC, Slob AK. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 2001; 51:1190-1195.
14. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001; 22:793-797.
15. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60:12-27.
16. Fisher WA, Rosen RC, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction. J Sex Med 2004; 1:150-160.
17. Sairam K, Kulinskaya E, Hanbury D, et al. Oral sildenafil (Viagra) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital. BMC Urol 2002; 2:4.
18. Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004; 328:1037.
19. Klotz T, Mathers M, Klotz R, Sommer F. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res 2005; 17:2-4.
20. Hatzichristou D, Moysidis K, Apostolidis A, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 nonresponders. Eur Urol 2005; 47:518-522; discussion 522-523.
21. Souverein PC, Egberts AC, Meuleman EJ, et al. Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J Impot Res 2002; 14:259-265.
22. Casabe A, Cobreros C, Bechara A, et al. Drop out reason in responders to sildenafil. Int J Impot Res 2001; 13:s5 [abstract #9].
23. Padma-nathan H, Eardley I, Kloner RA, et al. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002; 60:67-90.
24. Jiann BP, Yu CC, Su CC, Tsai JY. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006; 18:146-149.
25. Moreira SG Jr, Brannigan RE, Spitz A, et al. Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000; 56:474-476.
26. Wespes E, Rammal A, Garbar C. Sildenafil nonresponders: haemodynamic and morphometric studies. Eur Urol 2005; 48:136-139; discussion 139. This study provides structural data in sildenafil unresponsive erectile dysfunction men.
27. Althof SE. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 2002; 14 (Suppl 1):S99-S104.
28. Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 2002; 14 (Suppl 1):S43-S52.
29. Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170:2356-2358.
30. McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60:28-38.
31. Gruenwald I, Shenfeld O, Chen J, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006; 50:134-140. This study emphasizes the role of counseling and dose adjustment in achieving an excellent response to a second trial of sildenafil in patients with erectile dysfunction who had previously failed treatment with the drug.
32. McMahon CG. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res 2002; 14:533-538.
33. Khan MA, Morgan RJ, Mikhailidis DP. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin 2002; 18:103-107.
34. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19:95-98.
35. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172:255-258.
36. Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139:161-168.
37. Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002; 5:19-24.
38. Chung WS, Sohn JH, Park YY. Is obesity an underlying factor in erectile dysfunction? Eur Urol 1999; 36:68-70.
39. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291:2978-2984.
40. Derby CA, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56:302-306.
41. Lau DH, Kommu S, Mumtaz FH, et al. The management of phosphodiesterase-5 (PDE5) inhibitor failure. Curr Vasc Pharmacol 2006; 4:89-93.
42. Carson CC, Hatzichristou DG, Carrier S, et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004; 94:1301-1309.
43. Hatzichristou DG, Aliotta P, Auerbach S, et al. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis. Clin Ther 2005; 27:1452-1461.
44. Eardley I, Wright P, MacDonagh R, et al. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93:1271-1275.
45. Andersson KE, Hedlund P. New directions for erectile dysfunction therapies. Int J Impot Res 2002; 14 (Suppl 1):S82-S92.
46. Kendirci M, Hellstrom WJ. Intranasal apomorphine Nastech Pharmaceutical. IDrugs 2004; 7:483-488.
47. Hellstrom WJ, Kendirci M. Type 5 phosphodiesterase inhibitors: curing erectile dysfunction. Eur Urol 2006; 49:942-945.
48. Montorsi F, Briganti A, Salonia A, et al. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur Urol 2006; 49:979-986. Excellent review on the potential daily use of PDE-5 inhibitors.
49. Sommer F, Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol 2005; 23:385-392.
50. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004; 171:771-774.
51. Armagan A, Kim NN, Goldstein I, Traish AM. Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl 2006; 27:517-526. This excellent animal study suggests that testosterone at levels approaching one-tenth of the normal physiological plasma concentration may represent a threshold value, below which erectile function declines in a dose-dependent fashion.
52. Traish AM, Park K, Dhir V, et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140:1861-1868.
53. Aversa A, Isidori AM, Spera G, et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58:632-638.
54. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003; 6:94-99.
55. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172:658-663.
56. Rosenthal BD, May NR, Metro MJ, et al. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006; 67:571-574.
57. Greenstein A, Mabjeesh NJ, Sofer M, et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005; 173:530-532.
58. Andersson KE, Gemalmaz H, Waldeck K, et al. The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat. J Urol 1999; 161:1707-1712.
59. De Rose AF, Giglio M, Traverso P, et al. Combined oral therapy with sildenafil and doxazosin for the treatment of nonorganic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002; 14:50-53.
60. Russell S, McVary KT. Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man. Curr Urol Rep 2005; 6:445-453.
61. McVary KT, Swierzewski MJ, Monnig WB, et al. Sildenafil improves erectile function and concomitant lower urinary tract symptoms in men. In: American Urological Association Annual Meeting, Atlanta/Georgia; 2006 [abstract #920].
62. Kaplan SA, Gonzalez RR, Ogiste J, Te AE. Combination of an Alpha blocker, alfuzosin SR and a PDE-5 inhibitor, sildenafil citrate is superior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction. In American Urological Association Annual Meeting, Atlanta/Georgia; 2006 [abstract #1638].
63. Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 2005; 66:1080-1085.
64. Turner LA, Althof SE, Levine SB, et al. External vacuum devices in the treatment of erectile dysfunction: a one-year study of sexual and psychosocial impact. J Sex Marital Ther 1991; 17:81-93.
65. Vrijhof HJ, Delaere KP. Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic or mixed aetiology. Br J Urol 1994; 74:102-105.
66. Cookson MS, Nadig PW. Long-term results with vacuum constriction device. J Urol 1993; 149:290-294.
67. Soderdahl DW, Thrasher JB, Hansberry KL. Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Br J Urol 1997; 79:952-957.
68. Chen J, Mabjeesh NJ, Greenstein A. Sildenafil versus the vacuum erection device: patient preference. J Urol 2001; 166:1779-1781.
69. Chen J, Sofer M, Kaver I, et al. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol 2004; 171:292-295.
70. Raina R, Agarwal A, Allamaneni SS, et al. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 2005; 65:360-364.
71. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005; 65:1621-1650.
72. Nehra A, Blute ML, Barrett DM, Moreland RB. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res 2002; 14 (Suppl 1):S38-S42.
73. Raina R, Nandipati KC, Agarwal A, et al. Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl 2005; 26:757-760.
74. Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000; 38:30-34.
75. Jaffe JS, Antell MR, Greenstein M, et al. Use of intraurethral alprostadil in patients not responding to sildenafil citrate. Urology 2004; 63:951-954.
76. Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55:477-480.
77. Escrig A, Marin R, Mas M. Repeated PGE1 treatment enhances nitric oxide and erection responses to nerve stimulation in the rat penis by upregulating constitutive NOS isoforms. J Urol 1999; 162:2205-2210.
78. Gutierrez P, Hernandez P, Mas M. Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int J Impot Res 2005; 17:354-358. This study suggests that programmed intracavernous injections in combination with sildenafil can improve erectile function in men who were unresponsive to sildenafil alone.
79. McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999; 162:1992-1997; discussion 1997-1998.
80. Mydlo JH, Viterbo R, Crispen P. Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 2005; 95:843-846.
81. Baniel J, Israilov S, Segenreich E, Livne PM. Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. BJU Int 2001; 88:58-62.
82. Raina R, Lakin MM, Agarwal A, et al. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology 2004; 63:532-537; discussion 538.
83. Carson CC. Penile prostheses: are they still relevant? BJU Int 2003; 91:176-177.
84. Mulhall JP, Jahoda A, Aviv N, et al. The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ. BJU Int 2004; 93:97-99.